Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
Identifieur interne : 000092 ( Main/Corpus ); précédent : 000091; suivant : 000093Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
Auteurs : Bernard Scatton ; France Javoy-Agid ; Liliane Rouquier ; Bruno Dubois ; Yves AgidSource :
- Brain Research [ 0006-8993 ] ; 1983.
English descriptors
- KwdEn :
Abstract
Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinuedl-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuousl-DOPA treatment (i.e. having received the last dose ofl-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.
Url:
DOI: 10.1016/0006-8993(83)90993-9
Links to Exploration step
ISTEX:7BDFD6A652830103981F9D0118B8E0A5DC4971EALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title><author><name sortKey="Scatton, Bernard" sort="Scatton, Bernard" uniqKey="Scatton B" first="Bernard" last="Scatton">Bernard Scatton</name><affiliation><mods:affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</mods:affiliation></affiliation></author><author><name sortKey="Javoy Agid, France" sort="Javoy Agid, France" uniqKey="Javoy Agid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rouquier, Liliane" sort="Rouquier, Liliane" uniqKey="Rouquier L" first="Liliane" last="Rouquier">Liliane Rouquier</name><affiliation><mods:affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7BDFD6A652830103981F9D0118B8E0A5DC4971EA</idno><date when="1983" year="1983">1983</date><idno type="doi">10.1016/0006-8993(83)90993-9</idno><idno type="url">https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000092</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title><author><name sortKey="Scatton, Bernard" sort="Scatton, Bernard" uniqKey="Scatton B" first="Bernard" last="Scatton">Bernard Scatton</name><affiliation><mods:affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</mods:affiliation></affiliation></author><author><name sortKey="Javoy Agid, France" sort="Javoy Agid, France" uniqKey="Javoy Agid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rouquier, Liliane" sort="Rouquier, Liliane" uniqKey="Rouquier L" first="Liliane" last="Rouquier">Liliane Rouquier</name><affiliation><mods:affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1983">1983</date><biblScope unit="volume">275</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="328">328</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">7BDFD6A652830103981F9D0118B8E0A5DC4971EA</idno><idno type="DOI">10.1016/0006-8993(83)90993-9</idno><idno type="PII">0006-8993(83)90993-9</idno><idno type="ArticleID">83909939</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-hydroxyindoleacetic acid</term><term>Parkinson's disease</term><term>cortical areas</term><term>dihydroxyphenylacetic acid</term><term>dopamine</term><term>hippocampus</term><term>noradrenaline</term><term>serotonin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinuedl-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuousl-DOPA treatment (i.e. having received the last dose ofl-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Bernard Scatton</name><affiliations><json:string>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</json:string></affiliations></json:item><json:item><name>France Javoy-Agid</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</json:string></affiliations></json:item><json:item><name>Liliane Rouquier</name><affiliations><json:string>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</json:string></affiliations></json:item><json:item><name>Bruno Dubois</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</json:string></affiliations></json:item><json:item><name>Yves Agid</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cortical areas</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hippocampus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dihydroxyphenylacetic acid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>noradrenaline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>serotonin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>5-hydroxyindoleacetic acid</value></json:item></subject><articleId><json:string>83909939</json:string></articleId><language><json:string>eng</json:string></language><abstract>Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinuedl-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuousl-DOPA treatment (i.e. having received the last dose ofl-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.</abstract><qualityIndicators><score>7.94</score><pdfVersion>1.3</pdfVersion><pdfPageSize>548 x 756 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>8</keywordCount><abstractCharCount>1681</abstractCharCount><pdfWordCount>5433</pdfWordCount><pdfCharCount>28940</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>245</abstractWordCount></qualityIndicators><title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title><pii><json:string>0006-8993(83)90993-9</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>Vol. 19</volume><pages><last>24</last><first>1</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Dopamine, Advances in Biochemical Psychopharmacology</title></serie><host><volume>275</volume><pii><json:string>S0006-8993(00)X0815-3</json:string></pii><pages><last>328</last><first>321</first></pages><issn><json:string>0006-8993</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Brain Research</title><publicationDate>1983</publicationDate></host><categories><wos><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>1983</publicationDate><copyrightDate>1983</copyrightDate><doi><json:string>10.1016/0006-8993(83)90993-9</json:string></doi><id>7BDFD6A652830103981F9D0118B8E0A5DC4971EA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1983</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title><author><persName><forename type="first">Bernard</forename><surname>Scatton</surname></persName><affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</affiliation></author><author><persName><forename type="first">France</forename><surname>Javoy-Agid</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation></author><author><persName><forename type="first">Liliane</forename><surname>Rouquier</surname></persName><affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</affiliation></author><author><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation></author><author><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation></author></analytic><monogr><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="pISSN">0006-8993</idno><idno type="PII">S0006-8993(00)X0815-3</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1983"></date><biblScope unit="volume">275</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="328">328</biblScope></imprint></monogr><idno type="istex">7BDFD6A652830103981F9D0118B8E0A5DC4971EA</idno><idno type="DOI">10.1016/0006-8993(83)90993-9</idno><idno type="PII">0006-8993(83)90993-9</idno><idno type="ArticleID">83909939</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1983</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinuedl-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuousl-DOPA treatment (i.e. having received the last dose ofl-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>cortical areas</term></item><item><term>hippocampus</term></item><item><term>dopamine</term></item><item><term>dihydroxyphenylacetic acid</term></item><item><term>noradrenaline</term></item><item><term>serotonin</term></item><item><term>5-hydroxyindoleacetic acid</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1983-02-08">Registration</change><change when="1983">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><article version="5.0" xml:lang="en" docsubtype="fla"><item-info><jid>BRES</jid><aid>83909939</aid><ce:pii>0006-8993(83)90993-9</ce:pii><ce:doi>10.1016/0006-8993(83)90993-9</ce:doi><ce:copyright type="unknown" year="1983">Elsevier Science Publishers B.V., Amsterdam</ce:copyright></item-info><head><ce:title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</ce:title><ce:author-group><ce:author><ce:given-name>Bernard</ce:given-name><ce:surname>Scatton</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>France</ce:given-name><ce:surname>Javoy-Agid</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Liliane</ce:given-name><ce:surname>Rouquier</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Bruno</ce:given-name><ce:surname>Dubois</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Yves</ce:given-name><ce:surname>Agid</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</ce:textfn></ce:affiliation></ce:author-group><ce:date-accepted day="8" month="2" year="1983"></ce:date-accepted><ce:abstract id="ab1" class="author" xml:lang="en"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinued<ce:small-caps>l</ce:small-caps>-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuous<ce:small-caps>l</ce:small-caps>-DOPA treatment (i.e. having received the last dose of<ce:small-caps>l</ce:small-caps>-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword" xml:lang="en"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Parkinson's disease</ce:text></ce:keyword><ce:keyword><ce:text>cortical areas</ce:text></ce:keyword><ce:keyword><ce:text>hippocampus</ce:text></ce:keyword><ce:keyword><ce:text>dopamine</ce:text></ce:keyword><ce:keyword><ce:text>dihydroxyphenylacetic acid</ce:text></ce:keyword><ce:keyword><ce:text>noradrenaline</ce:text></ce:keyword><ce:keyword><ce:text>serotonin</ce:text></ce:keyword><ce:keyword><ce:text>5-hydroxyindoleacetic acid</ce:text></ce:keyword></ce:keywords></head><tail view="all"><ce:bibliography view="all" id="bibliography.0010"><ce:section-title>References</ce:section-title><ce:bibliography-sec id="bibliography-sec.0010"><ce:bib-reference id="bib1"><ce:label>1</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Agid</ce:surname><ce:given-name>Y.</ce:given-name></sb:author><sb:author><ce:surname>Javoy</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Glowinski</ce:surname><ce:given-name>J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature New Biol.</sb:maintitle></sb:title><sb:volume-nr>245</sb:volume-nr></sb:series><sb:date>1973</sb:date></sb:issue><sb:pages><sb:first-page>150</sb:first-page><sb:last-page>151</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2</ce:label><ce:other-ref><ce:textref>Agid, Y., Ruberg, M., Dubois, B. and Javoy-Agid, F., Biochemical substrates of mental disturbances in Parkinson disease. In<ce:italic>Advances in Neurology, Proceedings of the VII International Symposium on Parkinson Disease</ce:italic>, Raven Press, (in press).</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Argiolas</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Fadda</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Stefanini</ce:surname><ce:given-name>E.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A simple radioenzymatic method for determination of picogram amounts of 3,4-dihydroxyphenylacetic acid (DOPAC) in the rat brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>1977</sb:date></sb:issue><sb:pages><sb:first-page>599</sb:first-page><sb:last-page>601</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Azmitia</ce:surname><ce:given-name>E.</ce:given-name></sb:author><sb:author><ce:surname>Segal</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. comp. Neurol.</sb:maintitle></sb:title><sb:volume-nr>179</sb:volume-nr></sb:series><sb:date>1978</sb:date></sb:issue><sb:pages><sb:first-page>641</sb:first-page><sb:last-page>668</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bacopoulos</ce:surname><ce:given-name>N.G.</ce:given-name></sb:author><sb:author><ce:surname>Maas</ce:surname><ce:given-name>J.W.</ce:given-name></sb:author><sb:author><ce:surname>Hattox</ce:surname><ce:given-name>S.E.</ce:given-name></sb:author><sb:author><ce:surname>Roth</ce:surname><ce:given-name>R.H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Regional distribution of dopamine metabolites in human and primate brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Commun. Psychopharmacol.</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1978</sb:date></sb:issue><sb:pages><sb:first-page>281</sb:first-page><sb:last-page>286</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bannon</ce:surname><ce:given-name>M.J.</ce:given-name></sb:author><sb:author><ce:surname>Michaud</ce:surname><ce:given-name>R.L.</ce:given-name></sb:author><sb:author><ce:surname>Roth</ce:surname><ce:given-name>R.H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Molec. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>270</sb:first-page><sb:last-page>275</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bartholini</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:author><ce:surname>Pletscher</ce:surname><ce:given-name>A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Cerebral accumulation and metabolism of<ce:sup loc="pre">14</ce:sup>C-dopa after selective inhibition of peripheral decarboxylase</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pharmacol. exp. Ther.</sb:maintitle></sb:title><sb:volume-nr>161</sb:volume-nr></sb:series><sb:date>1968</sb:date></sb:issue><sb:pages><sb:first-page>14</sb:first-page><sb:last-page>20</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bernheimer</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Birkmayer</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Verteilung des 5-hydroxytryptamins (serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Klin. Wschr.</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:date>1961</sb:date></sb:issue><sb:pages><sb:first-page>1056</sb:first-page><sb:last-page>1059</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bernheimer</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Birkmayer</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:author><sb:author><ce:surname>Jellinger</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Seitelberger</ce:surname><ce:given-name>F.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Brain dopamine and the syndrome of Parkinson and Huntington. Clinical, morphological and neurochemical correlations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Sci.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>1973</sb:date></sb:issue><sb:pages><sb:first-page>415</sb:first-page><sb:last-page>455</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bondareff</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Mountjoy</ce:surname><ce:given-name>C.Q.</ce:given-name></sb:author><sb:author><ce:surname>Roth</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>164</sb:first-page><sb:last-page>168</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Brown</ce:surname><ce:given-name>R.M.</ce:given-name></sb:author><sb:author><ce:surname>Crane</ce:surname><ce:given-name>A.M.</ce:given-name></sb:author><sb:author><ce:surname>Goldman</ce:surname><ce:given-name>P.S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle></sb:title><sb:volume-nr>168</sb:volume-nr></sb:series><sb:date>1979</sb:date></sb:issue><sb:pages><sb:first-page>133</sb:first-page><sb:last-page>150</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Carlsson</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Windblad</ce:surname><ce:given-name>B.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural Transm.</sb:maintitle></sb:title><sb:volume-nr>38</sb:volume-nr></sb:series><sb:date>1976</sb:date></sb:issue><sb:pages><sb:first-page>271</sb:first-page><sb:last-page>276</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cross</ce:surname><ce:given-name>A.J.</ce:given-name></sb:author><sb:author><ce:surname>Joseph</ce:surname><ce:given-name>M.H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The concurrent estimation of the major monoamine metabolites in human and non-human primate brain by HPLC with fluorescence and electrochemical detection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Life Sci.</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>499</sb:first-page><sb:last-page>505</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Da Prada</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Zürcher</ce:surname><ce:given-name>G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Life Sci.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>1976</sb:date></sb:issue><sb:pages><sb:first-page>1161</sb:first-page><sb:last-page>1174</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Farley</ce:surname><ce:given-name>I.J.</ce:given-name></sb:author><sb:author><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Birkmayer</ce:surname><ce:given-name>W.</ce:given-name></sb:editor><sb:editor><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>Advances in Parkinsonism</sb:maintitle></sb:title><sb:date>1976</sb:date><sb:publisher><sb:name>Editions Roche Basel</sb:name></sb:publisher></sb:edited-book><sb:pages><sb:first-page>178</sb:first-page><sb:last-page>185</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Dopamine (3-hydroxytryptamine) and brain function</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharmacol. Rev.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1966</sb:date></sb:issue><sb:pages><sb:first-page>925</sb:first-page><sb:last-page>963</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17</ce:label><ce:other-ref><ce:textref>Javoy-Agid, F. Ruberg, M., Taquet, H., Bokobza, B., Agid, Y., Gaspar, P., Berger, B., N'Guyen-Legros, Alvarez, C., Gray, F., Escourolle, R., Scatton, B. and Rouquier, L., Biochemical neuropathology of Parkinson disease. In<ce:italic>Advances in Neurology, Proceedings of the VII International Symposium on Parkinson's Disease</ce:italic>, Raven Press, (in press).</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>18</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Javoy-Agid</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Taquet</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Berger</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Gaspar</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Morel-Maroger</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Montastruc</ce:surname><ce:given-name>J.L.</ce:given-name></sb:author><sb:author><ce:surname>Scatton</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Ruberg</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Agid</ce:surname><ce:given-name>Y.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Relations between dopamine and methionine-enkephalin systems in control and parkinsonian brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Katsuki</ce:surname><ce:given-name>S.</ce:given-name></sb:editor><sb:editor><ce:surname>Tsubaki</ce:surname><ce:given-name>T.</ce:given-name></sb:editor><sb:editor><ce:surname>Toyokura</ce:surname><ce:given-name>Y.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>International Congress, Series No. 568 Neurology</sb:maintitle></sb:title><sb:date>1981</sb:date><sb:publisher><sb:name>Excerpta Medica</sb:name><sb:location>Amsterdam</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>187</sb:first-page><sb:last-page>202</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>19</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lindvall</ce:surname><ce:given-name>O.</ce:given-name></sb:author><sb:author><ce:surname>Björklund</ce:surname><ce:given-name>A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Anatomy of the dopaminergic neuron systems in the rat brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition><sb:book-series><sb:editors><sb:editor><ce:surname>Roberts</ce:surname><ce:given-name>P.J.</ce:given-name></sb:editor><sb:editor><ce:surname>Woodruff</ce:surname><ce:given-name>G.N.</ce:given-name></sb:editor><sb:editor><ce:surname>Iversen</ce:surname><ce:given-name>L.L.</ce:given-name></sb:editor></sb:editors><sb:series><sb:title><sb:maintitle>Dopamine, Advances in Biochemical Psychopharmacology</sb:maintitle></sb:title><sb:volume-nr>Vol. 19</sb:volume-nr></sb:series></sb:book-series><sb:date>1978</sb:date><sb:publisher><sb:name>Raven Press</sb:name><sb:location>New York</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>24</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>20</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lloyd</ce:surname><ce:given-name>K.G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Neurochemical compensation in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Lakke</ce:surname><ce:given-name>J.P.</ce:given-name></sb:editor><sb:editor><ce:surname>Korf</ce:surname><ce:given-name>J.</ce:given-name></sb:editor><sb:editor><ce:surname>Wesseling</ce:surname><ce:given-name>H.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>Parkinson's Disease</sb:maintitle></sb:title><sb:date>1977</sb:date><sb:publisher><sb:name>Excerpta Medica</sb:name><sb:location>Amsterdam</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>61</sb:first-page><sb:last-page>72</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>21</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>514</sb:first-page><sb:last-page>539</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>22</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nyberg</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Adolfsson</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Andén</ce:surname><ce:given-name>N.E.</ce:given-name></sb:author><sb:author><ce:surname>Winblad</ce:surname><ce:given-name>B.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Concentrations of dopamine and noradrenaline in some limbic and related regions of the human brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta neurol. scand.</sb:maintitle></sb:title><sb:volume-nr>65</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>267</sb:first-page><sb:last-page>273</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>23</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Price</ce:surname><ce:given-name>K.S.</ce:given-name></sb:author><sb:author><ce:surname>Farley</ce:surname><ce:given-name>I.J.</ce:given-name></sb:author><sb:author><ce:surname>Hornykiewicz</ce:surname><ce:given-name>O.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:edition>2nd edn.</sb:edition><sb:book-series><sb:editors><sb:editor><ce:surname>Roberts</ce:surname><ce:given-name>P.J.</ce:given-name></sb:editor><sb:editor><ce:surname>Woodruff</ce:surname><ce:given-name>G.N.</ce:given-name></sb:editor><sb:editor><ce:surname>Iversen</ce:surname><ce:given-name>L.L.</ce:given-name></sb:editor></sb:editors><sb:series><sb:title><sb:maintitle>Dopamine, Advances in Biochemical Psychopharmacology</sb:maintitle></sb:title><sb:volume-nr>Vol. 19</sb:volume-nr></sb:series></sb:book-series><sb:date>1978</sb:date><sb:publisher><sb:name>Raven Press</sb:name><sb:location>New York</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>293</sb:first-page><sb:last-page>309</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>24</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Riederer</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Birkmayer</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Seemann</ce:surname><ce:given-name>D.</ce:given-name></sb:author><sb:author><ce:surname>Wuketich</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural Transm.</sb:maintitle></sb:title><sb:volume-nr>41</sb:volume-nr></sb:series><sb:date>1977</sb:date></sb:issue><sb:pages><sb:first-page>241</sb:first-page><sb:last-page>251</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>25</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rinne</ce:surname><ce:given-name>U.K.</ce:given-name></sb:author><sb:author><ce:surname>Sonninen</ce:surname><ce:given-name>V.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Brain catecholamines and their metabolites in parkinsonian patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch. Neurol.</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:date>1973</sb:date></sb:issue><sb:pages><sb:first-page>107</sb:first-page><sb:last-page>110</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>26</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Scatton</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Rouquier</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Javoy-Agid</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Agid</ce:surname><ce:given-name>Y.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Dopamine deficiency in the cerebral cortex in Parkinson disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>1039</sb:first-page><sb:last-page>1040</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>27</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Scatton</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Simon</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Le Moal</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Bischoff</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Origin of dopaminergic innervation of the rat hippocampal formation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosci. Lett.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1980</sb:date></sb:issue><sb:pages><sb:first-page>125</sb:first-page><sb:last-page>131</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>28</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Semerdjian-Rouquier</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Bossi</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Scatton</ce:surname><ce:given-name>B.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reversed-phase high-performance liquid chromatography with electrochemical detection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Chromatogr.</sb:maintitle></sb:title><sb:volume-nr>218</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>663</sb:first-page><sb:last-page>670</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>29</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Sloviter</ce:surname><ce:given-name>R.S.</ce:given-name></sb:author><sb:author><ce:surname>Connor</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Post mortem stability of norepinephrine, dopamine and serotonin in rat brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:date>1977</sb:date></sb:issue><sb:pages><sb:first-page>1129</sb:first-page><sb:last-page>1131</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>30</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Versteeg</ce:surname><ce:given-name>D.H.</ce:given-name></sb:author><sb:author><ce:surname>Van der Gugten</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>De Jong</ce:surname><ce:given-name>W.</ce:given-name></sb:author><sb:author><ce:surname>Palkovits</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Regional concentrations of noradrenaline and dopamine in rat brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle></sb:title><sb:volume-nr>113</sb:volume-nr></sb:series><sb:date>1976</sb:date></sb:issue><sb:pages><sb:first-page>563</sb:first-page><sb:last-page>574</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>31</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Wiesel</ce:surname><ce:given-name>F.A.</ce:given-name></sb:author><sb:author><ce:surname>Sedvall</ce:surname><ce:given-name>G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Post-mortem changes of dopamine and homovanillic acid levels in rat striatum as measured by mass fragmentography</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Research</sb:maintitle></sb:title><sb:volume-nr>65</sb:volume-nr></sb:series><sb:date>1974</sb:date></sb:issue><sb:pages><sb:first-page>547</sb:first-page><sb:last-page>550</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Scatton</namePart><affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">France</namePart><namePart type="family">Javoy-Agid</namePart><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Liliane</namePart><namePart type="family">Rouquier</namePart><affiliation>Biochemistry Unit, Synthélabo-L.E.R.S., 31 avenue Paul Vaillant-Couturier, 92220 Bagneux France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><affiliation>Laboratoire de Médecine Expérimentale, CHU PitiéSalpétrière, 91 Boulevard de L'Hoˆpital, 75634 Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1983</dateIssued><dateValid encoding="w3cdtf">1983-02-08</dateValid><copyrightDate encoding="w3cdtf">1983</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleceatic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantia amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinuedl-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuousl-DOPA treatment (i.e. having received the last dose ofl-DOPA 0–24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>cortical areas</topic><topic>hippocampus</topic><topic>dopamine</topic><topic>dihydroxyphenylacetic acid</topic><topic>noradrenaline</topic><topic>serotonin</topic><topic>5-hydroxyindoleacetic acid</topic></subject><relatedItem type="host"><titleInfo><title>Brain Research</title></titleInfo><titleInfo type="abbreviated"><title>BRES</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19830926</dateIssued></originInfo><identifier type="ISSN">0006-8993</identifier><identifier type="PII">S0006-8993(00)X0815-3</identifier><part><detail type="volume"><number>275</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>203</start><end>399</end></extent><extent unit="pages"><start>321</start><end>328</end></extent></part></relatedItem><identifier type="istex">7BDFD6A652830103981F9D0118B8E0A5DC4971EA</identifier><identifier type="DOI">10.1016/0006-8993(83)90993-9</identifier><identifier type="PII">0006-8993(83)90993-9</identifier><identifier type="ArticleID">83909939</identifier><accessCondition type="use and reproduction" contentType="">© 1983Elsevier Science Publishers B.V., Amsterdam</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science Publishers B.V., Amsterdam, ©1983</recordOrigin></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/7BDFD6A652830103981F9D0118B8E0A5DC4971EA/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:7BDFD6A652830103981F9D0118B8E0A5DC4971EA
|texte= Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |